Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB 57 Operating Cash Flow per Share is €0.24 as of Dec. 2025. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.60 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 762 Drug Manufacturers companies, Labiana Health ranks worse than 87.4% on this metric.
Labiana Health's operating cash flow per share for the
six
months ended in Dec. 2025 was €0.31.
Labiana Health's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.24.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Labiana Health was -75.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -28.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Labiana Health's Operating Cash Flow per Share or its related term are showing as below:
XMAD:LAB'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -28 Med: -2.75 Max: 22.5
Current: -28
During the past 6 years, Labiana Health's highest 3-Year average Operating Cash Flow per Share Growth Rate was 22.50% per year. The lowest was -28.00% per year. And the median was -2.75% per year.
XMAD:LAB's 3-Year OCF Growth Rate is ranked worse than 87.4% of 762
companies
in the Drug Manufacturers industry
Industry Median: 7.15
vs XMAD:LAB: -28.00
Labiana Health Operating Cash Flow per Share Related Terms
Labiana Health Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Labiana Health's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health Operating Cash Flow per Share Chart
XMAD:LAB vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Labiana Health's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of €0.24 mean?
Labiana Health (XMAD:LAB) has a Operating Cash Flow per Share of €0.24 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Labiana Health and its competitors. According to the industry distribution chart, Labiana Health ranks #666 out of 762 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is Labiana Health's Operating Cash Flow per Share too high?
Labiana Health's current Operating Cash Flow per Share is €0.24. Based on the distribution chart, Labiana Health ranks #666 out of 762 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #666 out of 762 companies for Operating Cash Flow per Share. This places Labiana Health in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.15, based on 762 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Operating Cash Flow per Share is €0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.60, compared to a current price of €6.35 — trading 76.4% above its estimated fair value. The current Operating Cash Flow per Share is €0.24. Labiana Health's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Operating Cash Flow per Share is €0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.35 is trading 76.4% above its estimated GF Value™ of €3.60.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Operating Cash Flow per Share: €0.24
GF Value™: €3.60 vs. price of €6.35 (76.4% above fair value)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
